Abstracts tagged "psoriasis and psoriatic arthritis"

Abstract Number: 1588 • 2018 ACR/ARHP Annual Meeting
Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia
Julia Tan¹, J. Antonio Avina-Zubieta², Alyssa Dominique³, Hamid Tavakoli⁴ and Teresa A Simon³, ¹Medicine, University of British Columbia, Vancouver, BC, Canada, ²Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Psoriasis (PsO) is a relapsing chronic autoimmune disease of the skin. Up to one-third of patients (pts) also develop inflammatory arthritis, known as psoriatic…
Abstract Number: 1589 • 2018 ACR/ARHP Annual Meeting
Cardiac Biomarkers and Carotid Atherosclerosis and Its Progression in Psoriatic Disease
Lihi Eder¹, Vinod Chandran², Iain B. McInnes³, Richard J. Cook⁴, Dafna D Gladman⁵, Paul Welsh⁶, Naveed Sattar⁷ and Paula Harvey⁸, ¹Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ³University of Glasgow, Glasgow, United Kingdom, ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶nstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁷Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁸Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Laboratory biomarkers indicative of cardiac ischemia or dysfunction improve cardiovascular (CV) risk stratification in the general population. Their utility in patients with psoriatic disease…
Abstract Number: 996 • 2017 ACR/ARHP Annual Meeting
Accuracy of Canadian Administrative Health Data in Identifying Patients with Psoriasis and Psoriatic Arthritis Using Primary Care Medical Records As the Reference Standard
Lihi Eder^1,2, Jessica Widdifield³, Cheryl F. Rosen⁴, Dafna D Gladman², Raed Alhusayen⁵, Michael Paterson⁶, Stephanie Cheng⁶, Shirin Jabbari⁶, Willemina Campbell⁷, Sasha Bernatsky⁸ and Karen Tu⁶, ¹Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Dermatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁶Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁷Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ⁸Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: We assessed the accuracy of algorithms to identify patients with psoriasis and psoriatic arthritis (PsA) in administrative health data in a validation set derived…
Abstract Number: 1558 • 2017 ACR/ARHP Annual Meeting
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis
Birju D. Bhatt¹, J. Lynn Palmer², Jeffrey R. Curtis³, Sathya Velkuru⁴ and Joel Kremer⁵, ¹Medicine, div-of Rheumatology, Albany Medical College, Albany, NY, ²Corrona Research Foundation, Albany, NY, ³Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, Albany Medical College, Albany, NY, ⁵Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Psoriasis is a complex disorder with cutaneous and rheumatological manifestations affecting 2-3% of the population of the Western world. The prevalence of hypertension (HTN)…
Abstract Number: 1571 • 2017 ACR/ARHP Annual Meeting
Bimekizumab Dual Inhibition of IL-17A and IL-17F Provides Evidence of IL-17F Contribution to Chronic Inflammation in Disease-Relevant Cells
Ash Maroof¹, Remi Okoye¹, Tim Smallie¹, Dominique Baeten^2,3, Sophie Archer¹, Catherine Simpson¹, Meryn Griffiths¹ and Stevan Shaw¹, ¹UCB Pharma, Slough, United Kingdom, ²UCB Pharma, Brussels, Belgium, ³University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17A and IL-17F share structural homology and have similar biologic function.1 Although the contribution of IL-17A to immune-mediated inflammatory diseases has been widely reported,1,2…
Abstract Number: 1577 • 2017 ACR/ARHP Annual Meeting
Deciphering the Role of the Tissue Microenvironment in Shaping the Immune Landscape in Psoriatic Arthritis
Jin Hui Sherlynn Chan¹, Ying Ying Leung², Warren Fong², Yi Wei Yeo², Bhairav Paleja¹, Liyun Lai¹, Suzan Saidin¹, Camillus Chua¹, Sharifah Nur Hazirah¹, Su Li Poh¹, Andrea Hsiu Ling Low² and Salvatore Albani^1,3, ¹SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: Psoriatic arthritis (PsA) occurs in a third of patients with psoriasis (Ps) and up to 30% of patients with PsA do not have an…
Abstract Number: 1912 • 2017 ACR/ARHP Annual Meeting
Broad Immunophenotyping Results: CCR10 Expressing CD8 T Cells Distinguish Psoriatic Arthritis from Psoriasis Limited to Skin Involvement
Emmerik F.A. Leijten^1,2, Tessa S. van Kempen^1,2, Michel A.M. Olde Nordkamp^1,2, Fleurieke H. Verhagen^2,3, Sanne Hiddingh^2,3, Jonas J.W. Kuiper^2,3, Marianne L. Boes^2,4 and Timothy R.D.J. Radstake^1,2, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Department of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Studies that compare the immune cell phenotype or function from patients with psoriatic arthritis (PsA) to patients with psoriasis limited to cutaneous involvement (Pso)…
Abstract Number: 2522 • 2017 ACR/ARHP Annual Meeting
Metabolic Syndrome, NAFLD and LIVER Stiffness in Psoriatic Arthritis and Psoriasis Patients: A CROSS-Sectional Study
Augusta Ortolan¹, Mariagrazia Lorenzin¹, Giulia Tadiotto¹, Francesca Oliviero¹, Ariela Hoxha¹, Marta Favero², Stefano Piaserico³, Leonardo Punzi¹ and Roberta Ramonda¹, ¹Rheumatology Unit, Department of Medicine DIMED, University of Padova, Padova, Italy, ²Rheumatology Unit,Department of Medicine DIMED, University of Padova, Padova, Italy, ³Dermatology Clinic, University of Padova, Padova, Italy
Background/Purpose: Metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD, potentially evolving into liver fibrosis-LF), are more frequent in patient with psoriasis (PsO) with respect…
Abstract Number: 2539 • 2017 ACR/ARHP Annual Meeting
The Contribution of Skin and Joint Improvements to the Health-Related Quality of Life of Patients with Active Psoriatic Arthritis
Arthur Kavanaugh¹, Alice B Gottlieb², Akimichi Morita³, Joseph Merola⁴, Julie Birt⁵, Chen-Yen Lin⁵, Catherine Shuler⁵ and Diamant Thaçi⁶, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Dermatology, New York Medical College, Vallhalla, NY, ³Dept of Geriatric & Environmental Dermatology, Nagoya City Univ Medical School, Nagoya, Japan, ⁴Clinical Unit for Research Innovation & Trials, Harvard Medical School, Boston, MA, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein Campus Luebeck, Ratzeburger Allee, Germany
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease affecting peripheral and axial joints. For patients with active psoriasis, the added burden of skin…
Abstract Number: 2549 • 2017 ACR/ARHP Annual Meeting
Achievement of Minimal Disease Activity Is Associated with Improvements in Health-Related Quality of Life and Productivity in Psoriatic Arthritis Patients
Laura C Coates¹, Ana-Maria Orbai², Julie Birt³, Lisa Kerr³, Olivier Benichou³ and Philip S. Helliwell⁴, ¹University of Oxford, Leeds, Great Britain, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Eli Lilly and Company, Indianapolis, IN, ⁴School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are moving toward attainment of absolute therapeutic thresholds rather than relative improvement. Minimal disease activity (MDA), a composite…
Abstract Number: 2879 • 2017 ACR/ARHP Annual Meeting
Switching from Adalimumab to Chs-1420: A Randomized, Double-Blind Global Clinical Trial in Patients with Psoriasis and Psoriatic Arthritis
Jennifer Hodge, Hong Tang, Paula O'Connor and Barbara Finck, Coherus BioSciences, Inc., Redwood City, CA
Background/Purpose: CHS-1420 is a proposed biosimilar to adalimumab. A phase 3, randomized, double-blind, multicenter study evaluated the equivalence of CHS-1420 to adalimumab in patients with…
Abstract Number: 2973 • 2017 ACR/ARHP Annual Meeting
Detection of Clinical Signs of Arthritis and Subclinical Evidence of Inflammation in Psoriasis Patients with Risk for Arthritis: Value of Clinical Examination, Ultrasound and Fluorescence-Optical Imaging – Results from the Prospective Multicentre Xciting Study
Michaela Koehm¹, Tanja Rossmanith², Hans-Eckhard Langer³, Marina Backhaus⁴, Gerd R. Burmester⁵, Siegfried Wassenberg⁶, Benjamin Köhler⁶, Harald Burkhardt⁷ and Frank Behrens⁸, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ³RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, ⁴Rheumatology, Park-Klinik Weissensee, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany, ⁶Rheumazentrum Ratingen, Ratingen, Germany, ⁷Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁸Clinical Research Rheumatology and Fraunhofer Institute IMETranslation, Goethe University, Frankfurt, Germany
Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso whereas the…
Abstract Number: 597 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors
Arthur Kavanaugh¹, Helena Marzo-Ortega², Ronald Vender³, Julie Birt⁴, David Adams⁴, Olivier Benichou⁴, Chen-Yen Lin⁴ and Peter Nash⁵, ¹Medicine, University of California, San Diego, La Jolla, CA, ²Department of Rheumatology, Chapel Allerton Hospital, Leeds, United Kingdom, ³Dermatrials Research, Inc., Hamilton, ON, Canada, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Queensland, Brisbane, Australia
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets interleukin-17A. Up to 24 weeks, IXE was superior to placebo (PBO) in improving…
Abstract Number: 607 • 2017 ACR/ARHP Annual Meeting
Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression up to 52 Weeks: An Overview from Secukinumab Phase 3 Clinical Trials
Philip J Mease¹, Mark Lebwohl², Isabelle Gilloteau³, Todd Fox³, Jaime Oliver³, Steffen Jugl³ and Alice B Gottlieb⁴, ¹University of Washington School of Medicine and Swedish Medical Center, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Novartis Pharma AG, Basel, Switzerland, ⁴Department of Dermatology, New York Medical College, Vallhalla, NY
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody selectively neutralizing interleukin-17A, exhibits significant efficacy, with a favorable safety profile, in the treatment of psoriatic arthritis…
Abstract Number: 628 • 2017 ACR/ARHP Annual Meeting
Integrated Efficacy Results from Two Phase 3 Trials of Ixekizumab for the Treatment of Psoriatic Arthritis
Bernard Combe¹, Peter Nash², David Adams³, Lisa Kerr³ and Olivier Benichou³, ¹Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ²University of Queensland, Brisbane, Australia, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A. Here, we present integrated efficacy data at Week 24 from two phase 3…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].